Business Wire

4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis


4Moving Biotech, a spin-off of 4P-Pharma dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

(Photo: Business Wire)

The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of intra-articular injection of Liraglutide (4P004). Thirty-four patients have been randomized in 3 sites in Belgium, EU.

"We are delighted to announce the end of patient recruitment. This accomplishment underscores our dedication to developing cutting-edge therapy that can profoundly impact the lives of patients with knee osteoarthritis." Revital Rattenbach, Executive Chairwoman of 4Moving Biotech

About 4P004

4P004, a GLP1 analog, is a novel first-in-class drug candidate addressing a high unmet medical need. The purpose is to potentially change the natural course of osteoarthritis to prevent long-term disability. Furthermore, it demonstrates solid anti-inflammatory and anti-catabolic properties by reducing the secretion of inflammatory cytokines and degradation enzymes within joint tissues.

"This is an important step in our efforts to rapidly translate our drug candidate into a safe and effective therapy. 4P004 offers hope for preventing long-term disability and improving the patient's life.” said Prof. Francis Berenbaum, Chief Medical Officer of 4Moving Biotech.

About LASARE Phase I clinical trial

LASARE is a Phase I clinical trial with 34 participants who received 4P004 or a placebo, with doses ranging from 0.3 mg to 3.0 mg.

This study consists of a single intra-articular injection into the target knee with osteoarthritis. The primary outcome is to investigate the safety and tolerability of 4P004. Monitoring of adverse events, vital signs, ECG, and laboratory results will span from Day 1 to Day 29.

“The achievement in patient recruitment for our Phase I brings us one step closer to our Phase IIB clinical trial, showcasing the commitment of the entire 4Moving Biotech team." said Mathilde Mérot, 4Moving BiotechDirector of Regulatory Affairs and Clinical Operations.

The Phase I clinical trial results are scheduled for Q1 2024.

About 4Moving Biotech
4Moving Biotech is a biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD) candidate 4P004. Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis.
4Moving Biotech was founded in July 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Pasteur Institute in Lille, France.
Site internet :

The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Jean-Raymond Dadjé -
0033 (0)6 30 06 12 13

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global donors pledge over US$777 million to defeat neglected tropical diseases and improve the lives of 1.6 billion people at the Reaching the Last Mile Forum at COP283.12.2023 15:40:00 CET | Press release

Global donors at the 2023 Reaching the Last Mile Forum today pledged a collective US$777.2 million to help control, eliminate, and eradicate neglected tropical diseases (NTDs), in a landmark push to accelerate progress towards achieving the goals outlined in the World Health Organization’s 2030 roadmap on NTDs. This press release features multimedia. View the full release here: Uniting efforts with NTD-endemic countries, donors answered the urgent call to step up the fight against NTDs in the face of climate change, and to work together to improve the lives of the 1.6 billion people worldwide affected by these devastating yet preventable diseases. The pledging event was hosted by Reaching the Last Mile (RLM), the global health initiative driven by the philanthropy of His Highness Sheikh Mohamed Bin Zayed Al Nahyan, President of the UAE, in partnership with the Bill & Melinda Gates Foundation. The forum took place on the first ev

Sharjah Celebrates the UAE’s 52nd Union Day3.12.2023 09:22:00 CET | Press release

Sharjah concluded the 52nd Union Day celebrations, which lasted for 12 days, with wide participation from all segments of society including government entities, private sector institutions, Emiratis, international residents, and visitors to the emirate. This press release features multimedia. View the full release here: From the Union Day celebration in Sharjah (Photo 1: AETOSWire) Over 200 activities organized by the Sharjah National Day Celebrations Committee took place in the cities of Sharjah, Mleiha, Dibba Al Hosn, Khorfakkan, Kalba, Al Bataeh, Al Mudam, Al Dhaid, and Al Hamriyah. Celebrations also took place in cultural and tourist areas as Al Dhaid Fort, the heritage villages in Al Hamriyah, Mleiha, Kalba. Other locations included Wadi Al Hilo, the National Park in Sharjah, Al Hosn Island Canal, Khorfakkan Amphitheatre, Kalba Lake, and Al Bataeh Public Park. His Excellency Khalid Jasim Al Midfa, Chairman of the Sharjah Na

IFRC-DREF calls on global donors to help the world ‘Stand Tall’ in the face of accelerating humanitarian need - supporting smarter and faster disaster relief3.12.2023 01:01:00 CET | Press release

The International Federation of Red Cross and Red Crescent Societies (IFRC) has launched a new campaign to address rapidly escalating climate driven humanitarian crises. It calls on global governments and international donors to support local emergency responders and disaster hit communities - helping them to Stand Tall with smarter and faster humanitarian funding. This press release features multimedia. View the full release here: Stand Tall in the face of disaster with IFRC-DREF Insurance. (Photo: Business Wire) The IFRC’s Disaster Response Emergency Fund (IFRC-DREF) is the quickest, most efficient and most transparent way of getting funding directly to local National Societies — both before and immediately after a crisis hits. Yet it faces growing pressure to anticipate and respond to multiple, simultaneous and complex crises around the world as a result of climate change. Today, 3.6 billion people live in areas highly suscep

11 Winners Recognised at Zayed Sustainability Prize Awards Ceremony held during COP28 UAE2.12.2023 03:15:00 CET | Press release

His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, today awarded the winners of the Zayed Sustainability Prize, the UAE’s pioneering global award in sustainability and humanitarianism, during a ceremony held at COP28 UAE in Expo City Dubai. This press release features multimedia. View the full release here: 11 winners of the Zayed Sustainability Prize Recognised at COP28 (Photo: AETOSWire) The Ceremony was attended by numerous heads of delegations participating in COP28, ministers, senior government officials, and Prize winners and finalists. His Highness congratulated the winners, praising their efforts in promoting sustainability and encouraging them to continue their important contributions in this field. His Highness emphasised that the UAE is steadfast in building upon its established legacy in sustainability, a foundation laid by the country’s Founding Father, the late Sheikh Zayed bin Sultan Al Nahyan.

Zextras Introduces Carbonio - A Private Digital Workplace1.12.2023 16:07:00 CET | Press release

Zextras, the leading email and collaboration solutions provider, introduced Carbonio - a private digital workplace for the public sector and regulated industries. Carbonio emerges as an exceptional solution for the public sector, enabling them to implement an extensive digital workspace for their internal teams and stakeholders. Delivering a suite of features that are not only comprehensive but also fully customizable, from emails and calendars to video meetings and file storage, Carbonio allows for superior adaptation to any unique technical requirements or business objectives. It is equally enticing for regulated industries to enhance their operations by providing secure software solutions tailored to meet the distinct security needs of their country and respective states. The platform is rooted in robust compliance with global data protection regulations, including the European General Data Protection Regulation (GDPR). This fosters a secure digital environment for users, ensuring t